CYP19A1 and neoplasm: High serum concentrations of the aromatase inhibitor (AI) are aimed at taking the desired action in the tumor, and exploring whether it would lead to systemic side effects by both reducing the systemic estrogen levels and inhibiting the autocrine production of estrogens.